Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies

Anna Nikonova, MDM, Stephen N. Caplan, MD, April Shamy, MDM, Martin Gyger

Blood (2016) 128 (22): 5676.

https://doi.org/10.1182/blood.V128.22.5676.5676

Published: 2016

Journal Articles

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Darrell White, Andrew Spencer, P. Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger

Blood (2016) 128 (22): 3318.

https://doi.org/10.1182/blood.V128.22.3318.3318

Published: 2016

Journal Articles

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Suzanne Trudel, MD, Darrell White, MD, Martin Gyger, MD, Jonahtan Kaufmann, MD, Andrzej Jakubowiak, MD PhD, Engin Gul, BSc, Lisa W Le, MSc, Zhihua Li, Donna Reece, Vishal Kukreti, MD FRCPC, Richard LeBlanc

Blood (2015) 126 (23): 4234.

https://doi.org/10.1182/blood.V126.23.4234.4234

Published: 2015

Journal Articles

Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients

Martin Gyger, Entezam Sahovic, Mohamed Aslam

Blood (1998) 92 (9): 3489–3490.

https://doi.org/10.1182/blood.V92.9.3489

Published: 1998

Journal Articles

Lymphoma Cell Burden in Progenitor Cell Grafts Measured by Competitive Polymerase Chain Reaction: Less Than One Log Difference Between Bone Marrow and Peripheral Blood Sources

Brigitte M. Léonard, Francis Hétu, Lambert Busque, Martin Gyger, Robert Bélanger, Claude Perreault, Denis-Claude Roy

Blood (1998) 91 (1): 331–339.

https://doi.org/10.1182/blood.V91.1.331

Published: 1998

NARROW

High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients

Lymphoma Cell Burden in Progenitor Cell Grafts Measured by Competitive Polymerase Chain Reaction: Less Than One Log Difference Between Bone Marrow and Peripheral Blood Sources

Email alerts

ASH Publications

American Society of Hematology

High-Dose Cyclophosphamide in Highly Refractory Multiple Myeloma Patients As a Bridge to Further Novel Therapies

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma

Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients

Lymphoma Cell Burden in Progenitor Cell Grafts Measured by Competitive Polymerase Chain Reaction: Less Than One Log Difference Between Bone Marrow and Peripheral Blood Sources

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only